From NAFLD to NASH and HCC: Pathogenetic Mechanisms and Therapeutic Insights

Author(s): Samuele De Minicis, Chris Day, Gianluca Svegliati-Baroni

Journal Name: Current Pharmaceutical Design

Volume 19 , Issue 29 , 2013

Become EABM
Become Reviewer


NAFLD is the most common liver disease worldwide but it is the potential evolution to cirrhosis and hepatocellular carcinoma (HCC) that makes NAFLD of such clinical importance. The current work provides an overview of the main mechanims and potential therapeutical insights involved in NAFLD, NASH, fibrosis and HCC progression.

Keywords: NAFLD, NASH, fibrosis, microbiota, bacterial translocation.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [5239 - 5249]
Pages: 11
DOI: 10.2174/1381612811319290006
Price: $65

Article Metrics

PDF: 72